Associate Sponsors

Kedaara Capital invests Rs 567 cr in Religare's health insurance arm

The equity infusion is in sync with the long term vision of the Company to be future-focused, explore its full potential and accelerate growth

Health insurance
This transaction will further the growth of the health insurance business for Religare and help RHICL to emerge as a stronger insurance player
IANS
2 min read Last Updated : Jun 13 2020 | 3:15 PM IST

Religare Group said it had completed a transaction with Kedaara group entity, Trishikhar Ventures LLP, for investments in its health insurance subsidiary called Religare Health Insurance Company Limited (RHICL).

This transaction will further the growth of the health insurance business for Religare and help RHICL to emerge as a stronger insurance player.

The equity infusion is in sync with the long term vision of the Company to be future-focused, explore its full potential and accelerate growth.
 


Rashmi Saluja, Executive Chairperson of Religare Enterprises Limited and Non-Executive Chairperson, Religare Health Insurance Company Limited, said, "Religare Health Insurance is a customer focused company ith strong fundamentals. This equity infusion will bolster the confidence of our shareholders in the competitive strength and sound business strategy of Religare.

"The capital infusion will help us to continue our investments in making Religare health Insurance a future-enabled organisation, committed to ensure the best customer experience. It is a matter of pride that Religare has attracted a marquee investor even in such tough economic times."

The total investment made by Kedaara to acquire shares of RHICL is Rs 567.31 crore which comprises of primary capital infusion of Rs 300 crore and Rs. 267.31 crore for the purchase of RHICL shares from the existing shareholders , including purchase of 6.39 per cent stake from the company against a consideration of Rs 200 crore. Following these transactions, the shareholding of the company in RHICL now stands at 72.02 per cent on a paid up capital basis, a company statement said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :ReligareHealth Insurancecapital infusion

Next Story